Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thy Lam

Nurse Practitioner, Psychiatric/Mental Health Vista, CA Nurse Practitioner

NPI 1083277255 CMS profile 11031582

550 W Vista Way Ste 407, Vista, CA 92083

Open in the dashboard

General payments

$121,096

1,277 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thy Lam of Vista, CA is reported in the CMS Open Payments database as having received $121,096 across 1,277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,382 409
2024 General $28,890 366
2023 General $16,463 306
2022 General $4,362 157
2021 General $998 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thy Lam
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Thy Lam were reported at $70,382. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Thy Lam Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $998 $166 $54–$482 $132
2022 $4,362 $195 $66–$559 $149
2023 $16,463 $233 $82–$673 $160
2024 $28,890 $236 $84–$688 $164
2025 $70,382 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $92,811 335 payments
  2. Indivior Inc. $5,159 91 payments
  3. Alkermes, Inc. $3,561 164 payments
  4. AbbVie, Inc. $3,422 69 payments
  5. Vanda Pharmaceuticals Inc. $3,021 83 payments
  6. Neurocrine Biosciences, Inc. $2,727 105 payments
  7. Janssen Pharmaceuticals, Inc $2,213 67 payments
  8. ITI, Inc. $2,154 126 payments
  9. Otsuka America Pharmaceutical, Inc. $2,097 93 payments
  10. E.R. Squibb & Sons, L.L.C. $1,624 44 payments
  11. Other $2,306 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $75,267 44 payments
  2. Food and Beverage $29,242 1,139 payments
  3. Travel and Lodging $14,330 74 payments
  4. Consulting Fee $1,238 2 payments
  5. Education $1,019 18 payments
Products named General payments · program years 2021–2025
  1. UZEDY $53,833 185 payments
  2. Austedo XR $35,616 97 payments
  3. PERSERIS $5,159 91 payments
  4. VRAYLAR $3,388 68 payments
  5. FANAPT $3,021 83 payments
  6. LYBALVI $2,762 128 payments
  7. INGREZZA $2,582 99 payments
  8. AUSTEDO $2,531 43 payments
  9. HETLIOZ $2,327 75 payments
  10. ARISTADA $2,239 123 payments
  11. Other $20,485 916 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,506

Median for Nurse Practitioner: 389

Drug cost

$2,326,075

Median for Nurse Practitioner: $21,885

Branded share of claims

33.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 70 $803,315
Ingrezza Valbenazine Tosylate Brand 59 $487,752
Invega Sustenna Paliperidone Palmitate Brand 76 $221,132
Abilify Asimtufii Aripiprazole Brand 35 $174,131
Invega Trinza Paliperidone Palmitate Brand 20 $172,593
Perseris Risperidone Brand 38 $112,898
Uzedy Risperidone Brand 27 $96,469
Aristada Aripiprazole Lauroxil Brand 26 $81,095
Rexulti Brexpiprazole Brand 32 $43,260
Caplyta Lumateperone Tosylate Brand 25 $39,417

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,399

Medicare's payments for the services billed

Medicare patients

40

Average age 51

Services billed

143

18 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 35%
Depression 30%
Diabetes 28%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
$12,038 27 —
Austedo XR
$7,233 70 —
VRAYLAR
$2,727 — —
FANAPT
$891 — —
INGREZZA
$716 59 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

1,277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record